Decision analysis model for hepatitis B prophylaxis one year after liver transplantation
Sammy Saab, Maggie Y. Ham, Michael A. Stone, Curtis Holt, Myron Tong – 26 March 2009 – In patients receiving orthotopic liver transplantation, hepatitis B recurrence rates have decreased significantly with the use of various methods for prophylaxis. At present, a combination of hepatitis B immunoglobulin (HBIG) and lamivudine is the standard of care, resulting in recurrence rates of 0% to 11%. Recent data suggest that the addition of adefovir to lamivudine is successful in treating patients with recurrent hepatitis B infection.